The nominating institution CNRC on the project:
Shen offers a robust living cell platform that is widely accepted by regulatory authorities for manufacturing human vaccines. It has been used as a technology platform for development, and has potential for high-yield manufacturing of established vaccines or novel vaccines for emerging diseases, at a lower cost. This breakthrough will have a long-term impact.
Tags: Bio-Tech, COVID-19